Company:  FLUIDIGM CORP (FLDM)
Form Type:  S-8
Filing Date:  2/21/2014 
CIK:  0001162194 
Address:  7000 SHORELINE COURT
SUITE 100
 
City, State, Zip:  SOUTH SAN FRANCISCO, California 94080 
Telephone:  (650) 266-6000 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$5.95  
Change: 
0.00 (0.00%)  
Trade Time: 
12:51 PM EST  
Market Cap: 
$441.01M
Trade FLDM now with

© 2020  
Description of Business
Fluidigm is a global company that improves life through comprehensive health insight. Our innovative patented technologies and multi-omic tools are used by researchers to reveal meaningful insights into health and disease, identify biomarkers to inform decisions, and accelerate the development of more effective therapies. We create, manufacture, and market a range of products and services, including instruments, reagents and software that are used by researchers worldwide. Our focus is on the most pressing needs in translational and clinical research, including cancer, immunology and immunotherapy. We use proprietary CyTOF® and microfluidics technologies to develop innovative end-to-end solutions that have the flexibility required to meet the needs of translational research and the robustness to support high-impact clinical research studies. Our mass cytometry Helios(TM) system deeply profiles cell phenotype and function.
Register and access this filing in:     
  FORM S-8
    CALCULATION OF REGISTRATION FEE
    TABLE OF CONTENTS
    FORWARD-LOOKING STATEMENTS
    RISK FACTORS
    USE OF PROCEEDS
    SELLING STOCKHOLDERS
      BENEFICIAL OWNERS
    PLAN OF DISTRIBUTION
    LEGAL MATTERS
    EXPERTS
      INCORPORATION OF DOCUMENTS BY REFERENCE.
    WHERE YOU CAN FIND MORE INFORMATION
    PART II
    ITEM 4. DESCRIPTION OF SECURITIES.
      ITEM 6. INDEMNIFICATION OF DIRECTORS AND OFFICERS.
      ITEM 7. EXEMPTION FROM REGISTRATION CLAIMED.
      ITEM 8. EXHIBITS.
      ITEM 9. UNDERTAKINGS.
    SIGNATURES
    INDEX TO EXHIBITS
  EXHIBIT 4.3
  EXHIBIT 4.4
  EXHIBIT 4.5
  EXHIBIT 4.6
  EXHIBIT 4.7
  EXHIBIT 4.8
  EXHIBIT 4.9
  EXHIBIT 4.10
  EXHIBIT 5.1
  EXHIBIT 23.1
    Consent of Ernst & Young LLP, Independent Registered Public ...
  EXHIBIT 23.3
    Consent of Independent Registered Public Accounting Firm